Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MRNA |
---|---|---|
09:32 ET | 58569 | 65.5701 |
09:34 ET | 29149 | 65.15 |
09:36 ET | 17488 | 65.135 |
09:38 ET | 17455 | 65.2667 |
09:39 ET | 13976 | 65.275 |
09:41 ET | 55781 | 65.2532 |
09:43 ET | 15294 | 65.2 |
09:45 ET | 11926 | 65.22 |
09:48 ET | 20466 | 65.38 |
09:50 ET | 10285 | 65.415 |
09:52 ET | 9390 | 65.26 |
09:54 ET | 10389 | 65.4 |
09:56 ET | 13056 | 65.39 |
09:57 ET | 10773 | 65.29 |
09:59 ET | 16012 | 65.15 |
10:01 ET | 14146 | 65.29 |
10:03 ET | 20989 | 65.39 |
10:06 ET | 14374 | 65.6569 |
10:08 ET | 16485 | 65.47 |
10:10 ET | 23513 | 65.43 |
10:12 ET | 9851 | 65.48 |
10:14 ET | 33761 | 65.545 |
10:15 ET | 21238 | 65.44 |
10:17 ET | 1550 | 65.23 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Moderna Inc | 25.3B | -4.3x | --- |
ICON PLC | 25.1B | 34.9x | +4.68% |
Biontech SE | 26.7B | -48.4x | --- |
Biogen Inc | 29.0B | 24.9x | -18.14% |
Grifols SA | 7.1B | 35.4x | --- |
Beigene Ltd | 22.5B | -39.7x | --- |
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $25.3B |
---|---|
Revenue (TTM) | $5.1B |
Shares Outstanding | 384.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.67 |
EPS | $-15.37 |
Book Value | $36.27 |
P/E Ratio | -4.3x |
Price/Sales (TTM) | 5.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -91.78% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.